Senses Disorder TRIZ Cases

Chimeric fusion protein comprising FLT-1 and KDR domains inhibits neovascularization while maintaining efficacy for seven months with single administration.

Modifying molecular parameters of pyrazolyl urea compounds balances receptor affinity against metabolic stability, improving oral bioavailability.

Adding calcium chloride and heparin precipitates fibrinogen, preventing clot formation while preserving growth factors in platelet lysates.

An agent inhibiting the ubiquitinating enzyme Klhl18 reduces retinal light sensitivity and protects photoreceptor cells from degeneration.

Novel substituted piperidines block C5a receptor activity, addressing the lack of effective small molecule treatments for autoimmune disorders.

Amino-indolyl-substituted imidazolyl-pyrimidines inhibit Syk kinase activity via multi-point binding, resolving specificity limitations in current inhibitors.

Compounds inhibit alpha-crystallin aggregation to restore lens transparency, replacing surgical intervention with non-surgical pharmacological treatment.

Humanized antibodies replace murine variable domains with human sequences to maintain specific binding affinity for alpha v beta 6 integrins.

Crystalline dibenzo azepine derivatives enable intratympanic hair cell regeneration, resolving ototoxicity trade-offs in hearing loss treatments.

Near-infrared illumination with water-soluble chlorophyll derivatives induces collagen crosslinking, reducing toxicity and improving tissue penetration.

Benzylic glycoside derivatives inhibit the sodium-dependent glucose cotransporter 2 to increase urinary glucose excretion.

A recombinant yeast-derived enzyme mutant mimics alpha-galactosidase activity to degrade substrates in affected tissues.

Combining pioglitazone with pamapimod addresses dry age-related macular degeneration by targeting multiple pathological pathways simultaneously.

A customized artificial tear composition treats dry eye syndrome by matching viscosity and oil content to individual patient symptoms.

A synthetic peptide sequence increases nestin expression in astrocytes to promote neural stem cell generation.

Combining tamarind seed polysaccharide with hyaluronic acid creates a synergistic tear substitute that adheres to the ocular surface.

Substituted pyridine compounds inhibit the Wnt signaling pathway, resolving stability and solubility contradictions for pharmaceutical formulation.

Pyrazolopyrimidine derivatives modulate mGluR5 receptors to provide neuroprotection and cognitive improvement for Alzheimer's and Parkinson's disease.

LFA-1 antagonists block ICAM binding to reduce inflammation and prevent disease progression in diabetic retinopathy.

2,6-Quinolinyl derivatives selectively inhibit alpha4 integrins to treat inflammatory diseases.

Recombinant adeno-associated viral vectors deliver functional guanylate cyclase cDNA to restore retinal enzyme activity.

Fungal fermentation of Withania Somnifera eliminates toxicity while preserving anti-angiogenic activity.

Cyclohexapeptide somatostatin analogues substitute tryptophan with aromatic residues to bind multiple receptor subtypes simultaneously.

Formula II compounds modulate ABC transporter activity, addressing defective protein trafficking and restoring ion transport for cystic fibrosis treatment.

Direct oxidation of tertiary amines yields (+)-morphinanium N-oxides that inhibit VEGF without interacting with opiate receptors.

Aerosolized Gβγ inhibitors block Gi signaling to prevent PDE4 upregulation and desensitization during chronic asthma treatment.

Phosphorous progroups mask 2,4-pyrimidinediamine compounds to increase water solubility and oral bioavailability for treating Fc receptor diseases.

Purified collagenase degrades subconjunctival scar tissue to restore aqueous drainage and lower intraocular pressure after glaucoma surgery.

A microneedle device with a variable diameter lumen reduces insertion force while preventing leakage during posterior eye treatment.

Substituted dihydropyrazolone compounds stabilize hypoxia-inducible factor proteins to promote nuclear translocation.

Antibodies targeting C3d fragments deliver therapeutic agents to specific complement activation sites, reducing systemic side effects.

Non-competing anti-C5 antibody combinations block C5 cleavage, preventing membrane attack complex formation and reducing hemolysis in PNH patients.

Novel pyrrolidine sulfonamide analogs block calcium entry through TRPV4 channels, preventing pulmonary edema and inflammation in heart failure patients.

Selective PI3K delta gamma inhibitors reduce lung neutrophil influx while sparing systemic toxicity via topical administration.

Extracting the bioactive hexamer TX1EX2X3E from TNF-alpha creates a cyclic peptide that restores endothelial function without inducing inflammatory responses.

A lacrimal implant uses a fluid-absorbing hydrogel element to expand within the canaliculus and secure retention.

Lyophilized epinephrine compositions with metal chelators eliminate preservative-induced toxicity while maintaining stability for intraocular use.

Ionizing radiation crosslinks unmodified type I collagen to maintain transparency while improving mechanical strength for corneal sealing.

Segmented synthesis of covalently modified immodulator peptides resolves the trade-off between therapeutic efficacy and manufacturing complexity.

Plasmacytoid dendritic cells reduce neovascularization and inflammation while promoting nerve regeneration in ocular tissues.

Formula A cannabinoid compounds bind selectively to CB1 and CB2 receptors for targeted therapeutic applications.

Halorhodopsin channelrhodopsin fusion protein restores retinal light sensitivity, overcoming high threshold intensity limits of single-protein therapies.

Segmented Cas12b polypeptides reassemble into active nuclease complexes, reducing construct size for efficient viral delivery.

Structural optimization of quinazoline cores reduces safety issues while improving efficacy against Type 1 diabetes and macular degeneration.

Selective CDK4/6 inhibitors induce pharmacologic quiescence in hematopoietic stem cells to shield them from chemotherapy-induced DNA damage.

5-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines inhibit ALK1 kinase to treat angiogenesis-related disorders.

Antisense oligonucleotides target natural antisense transcripts to up-regulate Methionine Sulfoxide Reductase A expression in patient cells.